GH/IGF-1 axis in a large cohort of ß-thalassemia major adult patients: a cross-sectional study.
Adult
Beta-thalassemia
Growth hormone
Growth hormone deficiency
IGF-1
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
06
10
2021
accepted:
03
03
2022
pubmed:
20
3
2022
medline:
14
6
2022
entrez:
19
3
2022
Statut:
ppublish
Résumé
GH deficit (GHD) could represent an endocrine issue in ß-Thalassemia Major (ßTM) patients. GH/IGF-1 axis has not been extensively explored in ßTM adults, so far. We aim to assess GHD and IGF-1 deficiency prevalence in ßTM adult population, focusing on the relationship with liver disease. Cross-sectional multi-centre study conducted on 81 adult ßTM patients (44 males, mean age 41 ± 8 years) on transfusion and chelation therapy. GHD was investigated by GHRH + arginine test. IGF-1 levels, routine biochemical exams, Fibroscan, Hepatic Magnetic Resonance Imaging (MRI) and pituitary MRI were collected. Eighteen patients were affected by GHD and 63 were not (nGHD) according to GHRH + arginine test, while basal GH levels did not differ. GHD was associated with a higher BMI and a worse lipid profile (p < 0.05). No significant differences were observed regarding liver function between the two groups. Pituitary MRI scan was normal except for one case of empty sella. The 94.4% and 93.6% of GHD and nGHD, respectively, presented lower IGF-1 levels than the reference range, and mean IGF-1 SDS was significantly lower in GHD patients. GHD is frequent in adult ßTM patients and is associated with higher BMI and worse lipid profile. nGHD patients present lower IGF-1 levels as well. There was no relationship between IGF-1 levels and liver disease. Further, multicentric studies with larger cohorts and standardized diagnostic protocols are needed.
Identifiants
pubmed: 35305249
doi: 10.1007/s40618-022-01780-z
pii: 10.1007/s40618-022-01780-z
pmc: PMC9184367
doi:
Substances chimiques
IGF1 protein, human
0
Lipids
0
Human Growth Hormone
12629-01-5
Insulin-Like Growth Factor I
67763-96-6
Arginine
94ZLA3W45F
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1439-1445Informations de copyright
© 2022. The Author(s).
Références
Weatherall DJ (1998) 4 Pathophysiology of thalassaemia. Baillière’s Clin Haematol 11(1):127–146
doi: 10.1016/S0950-3536(98)80072-3
Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V, editors (2014) Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT) [Internet]. 3rd ed. Nicosia (CY): Thalassaemia International Federation. http://www.ncbi.nlm.nih.gov/books/NBK269382/ . Cited 30 Jun 2021
Karadag SIK, Karakas Z, Yilmaz Y, Gul N, Demir AA, Bayramoglu Z et al (2020) Pituitary iron deposition and endocrine complications in patients with β-thalasse. Hemoglobin 44(5):344–348
doi: 10.1080/03630269.2020.1812636
Mohammadian S, Bazrafshan HR, Sadeghi-Nejad A (2003) Endocrine gland abnormalities in thalassemia major: a brief review. J Pediatr Endocrinol Metab 16(7):957–964
doi: 10.1515/JPEM.2003.16.7.957
Bordbar M, Bozorgi H, Saki F, Haghpanah S, Karimi M, Bazrafshan A et al (2019) Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients: a historical cohort study in Southern Iran. J Endocrinol Invest 42(12):1467–1476
doi: 10.1007/s40618-019-01072-z
Casale M, Forni GL, Cassinerio E, Pasquali D, Origa R, Serra M et al (2021) Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multicentre nation-wide cohort. Haematologica. https://doi.org/10.3324/haematol.2020.272419
doi: 10.3324/haematol.2020.272419
pmcid: 8804575
Kanbour I, Chandra P, Soliman A, De Sanctis V, Nashwan A, Abusamaan S et al (2018) Severe liver iron concentrations (LIC) in 24 patients with β-thalassemia major: correlations with serum ferritin, liver enzymes and endocrine complications. Mediterr J Hematol Infect Dis 10(1):e2018062
pubmed: 30416694
pmcid: 6223579
De Sanctis V, Elsedfy H, Soliman A, Elhakim I, Soliman N, Elalaily R et al (2016) Endocrine profile of β-thalassemia major patients followed from childhood to advanced adulthood in a tertiary care center. Indian J Endocr Metab 20(4):451
doi: 10.4103/2230-8210.183456
Scacchi M, Danesi L, Cattaneo A, Valassi E, Giraldi FP, Argento C et al (2007) Growth hormone deficiency (GHD) in adult thalassaemic patients. Clin Endocrinol 67(5):790–795
doi: 10.1111/j.1365-2265.2007.02965.x
La Rosa C, De Sanctis V, Mangiagli A, Mancuso M, Guardabasso V, Galati MC et al (2005) Growth hormone secretion in adult patients with thalassaemia. Clin Endocrinol 62(6):667–671
doi: 10.1111/j.1365-2265.2005.02276.x
Vidergor G, Goldfarb AW, Glaser B, Dresner-Pollak R (2007) Growth hormone reserve in adult beta thalassemia patients. Endocrine 31(1):33–37
doi: 10.1007/s12020-007-0018-7
Scacchi M, Danesi L, Cattaneo A, Valassi E, Giraldi FP, Argento C et al (2008) Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites. Clin Endocrinol 69(2):202–207
doi: 10.1111/j.1365-2265.2008.03191.x
De Sanctis V, Skordis N, Galati MC, Raiola G, Giovannini M, Candini G et al (2011) Growth hormone and adrenal response to intramuscular glucagon test and its relationship to IGF-1 production and left ventricular ejection fraction in adult B-thalassemia major patients. Pediatr Endocrinol Rev 8(Suppl 2):290–294
pubmed: 21705980
Pincelli AI, Masera N, Tavecchia L, Perotti M, Perra S, Mariani R et al (2011) GH deficiency in adult B-thalassemia major patients and its relationship with IGF-1 production. Pediatr Endocrinol Rev 8(Suppl 2):284–289
pubmed: 21705979
Poggi M, Pascucci C, Monti S, Pugliese P, Lauri C, Amodeo G et al (2010) Prevalence of growth hormone deficiency in adult polytransfused β-thalassemia patients and correlation with transfusional and chelation parameters. J Endocrinol Invest 33(8):534–538
doi: 10.1007/BF03346643
Soliman A, De Sanctis V, Yassin M, Abdelrahman M (2014) Growth hormone—insulin-like growth factor-I axis and bone mineral density in adults with thalassemia major. Indian J Endocr Metab 8(1):32
doi: 10.4103/2230-8210.126525
De Sanctis V (2014) Insulin-like growth factor-1 (IGF-1): demographic, clinical and laboratory data in 120 consecutive adult patients with thalassaemia major. Mediterr J Hematol Infect Dis 6(1):e2014074. https://doi.org/10.4084/MJHID.2014.074
doi: 10.4084/MJHID.2014.074
pubmed: 25408860
pmcid: 4235482
Scacchi M, Danesi L, Cattaneo A, Sciortino G, Radin R, Ambrogio AG et al (2016) Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins. Endocrine 53(2):551–557
doi: 10.1007/s12020-016-0865-1
Tat LK (2020) Prevalence of endocrine complications in transfusion dependent thalassemia in Hospital Pulau Pinang: a pilot study. Med J Malay 75(1):33–37
Campo MR, Farese A, Correale M, Berti G, Massa M, Sorrentino MR et al (2018) Retrospective analysis of endocrine dysfunctions in a population of adult polytransfused patients: correlation of GH-IGF1 axis alteration with cardiac performance. Biomed Res Int 2018:6047801. https://doi.org/10.1155/2018/6047801
doi: 10.1155/2018/6047801
pubmed: 30356378
pmcid: 6178148
De Sanctis V, Soliman A, Elsedfy H, Skordis N, Kattamis C, Angastiniotis M et al (2013) Growth and endocrine disorders in thalassemia: the international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocr Metab 17(1):8–18. https://doi.org/10.4103/2230-8210.107808
doi: 10.4103/2230-8210.107808
Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML (2011) Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(6):1587–1609
doi: 10.1210/jc.2011-0179
Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R et al (2016) Hormonal replacement in hypopituitarism in adults: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101(11):3888–3921
doi: 10.1210/jc.2016-2118
Corneli G, Di Somma C, Baldelli R, Rovere S, Gasco V, Croce CG et al (2005) The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol 153(2):257–264
doi: 10.1530/eje.1.01967
Jobanputra M, Paramore C, Laird SG, McGahan M, Telfer P (2020) Co-morbidities and mortality associated with transfusion-dependent beta-thalassaemia in patients in England: a 10-year retrospective cohort analysis. Br J Haematol 191(5):897–905
doi: 10.1111/bjh.17091
Pinto VM, Poggi M, Russo R, Giusti A, Forni GL (2019) Management of the aging beta-thalassemia transfusion-dependent population—the Italian experience. Blood Rev 38:100594
doi: 10.1016/j.blre.2019.100594
Yılmaz K, Kan A, Çetincakmak MG, Uzel VH, Yılmaz D, Deniz MA et al (2021) Relationship between pituitary siderosis and endocrinological disorders in pediatric patients with beta-thalassemia. Cureus 13(1):e12877. https://doi.org/10.7759/cureus.12877
doi: 10.7759/cureus.12877
pubmed: 33633906
pmcid: 7899051
Di Somma C, Scarano E, Savastano S, Savanelli MC, Pivonello R, Colao A (2017) Cardiovascular alterations in adult GH deficiency. Best Pract Res Clin Endocrinol Metab 31(1):25–34
doi: 10.1016/j.beem.2017.03.005
Yassin MA, Soliman AT, de Sanctis V, Abdula MA, Riaz LM, Ghori FF et al (2018) Statural growth and prevalence of endocrinopathies in relation to liver iron content (LIC) in adult patients with beta thalassemia major (BTM) and sickle cell disease (SCD). Acta Biomed 89(2S):33–40. https://doi.org/10.23750/abm.v89i2-S.7085
doi: 10.23750/abm.v89i2-S.7085
pubmed: 29633731
pmcid: 6179098